Content about Anti-diabetic drugs

July 28, 2011
Bydureon reply submitted to FDA

Drug makers Eli Lilly, Amylin Pharmaceuticals and Alkermes are giving their long-acting form of an injected drug for Type 2 diabetes another try at the Food and Drug Administration.

July 22, 2011
Study: Metformin use during adolescence may help girls delay, prevent PCOS

A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

July 14, 2011
Takeda pulls two diabetes drugs off French market

OSAKA, Japan — Two diabetes drugs made by Takeda Pharmaceutical Co. have been pulled from the market in France due to evidence that their use may increase the risk of bladder cancer, Takeda said.

Takeda said its French subsidiary, Laboratoires Takeda, would withdraw Actos (pioglitazone) and Competact (pioglitazone and metformin). In addition, Takeda said it was cooperating with the European Medicines Agency in a pan-European of pioglitazone. Competact is marketed in the United States under the brand name Actoplus Met.

July 8, 2011
Decision Resources: Victoza may outpace Byetta

Novo Nordisk could be outpacing Eli Lilly and Amylin Pharmaceuticals in the diabetes wars, according to an analysis by healthcare market research firm Decision Resources.

July 6, 2011
Exenatide improves glucose control among diabetes patients in mid-stage trial

A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

July 6, 2011
MannKind: Patients have better view of insulin therapy when using Afrezza

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

June 29, 2011
Adding dapagliflozin to diabetes regimen may help reduce blood sugar, weight among patients

Adding an investigational drug for Type 2 diabetes to the common generic drug metformin helped control blood sugar in patients who could not control their blood sugar with metformin alone, according to results of a late-stage clinical study.

June 28, 2011
AstraZeneca, BMS say late-stage trial of Onglyza met primary endpoint

A cobranded Type 2 diabetes treatment may help reduce blood-sugar levels among patients when combined with insulin (with or without metformin), according to a late-stage clinical trial.

June 28, 2011
Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions

A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.

June 28, 2011
Study: Tradjenta reduces blood sugar, weight among patients

New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.

June 27, 2011
Adding Byetta to diabetes regimen could cut heart failure risk

Use of a drug for Type 2 diabetes made by Eli Lilly and Amylin Pharmaceuticals may lower patients’ risk of heart failure, according to a new study.

June 27, 2011
Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin

Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

June 27, 2011
Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment

An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.

June 20, 2011
Lilly, BI gear up to present data from studies of diabetes drugs

Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 15, 2011
Tradjenta now available in U.S. pharmacies

A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday.

June 13, 2011
Merck revises labels for 16 drugs

The Food and Drug Administration has approved changes to the labels of several drugs made by Merck, the agency said Friday.

June 9, 2011
Court vacates Amylin restraining order against Eli Lilly

A federal court has ruled in favor of drug maker Eli Lilly & Co. in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.

June 9, 2011
FDA approves labeling change for Eli Lilly insulin product

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

June 6, 2011
Study: Amylin's metreleptin improves diabetes, lipid control among patients

An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

June 2, 2011
Insulet acquires Neighborhood Diabetes

A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

May 31, 2011
Sanofi: Lyxumia won't significantly increase hypoglycemia risk

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

May 26, 2011
Court grants Amylin temporary restraining order to bar Lilly from using same sales team

Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

May 19, 2011
Avandia to be available only by mail order in November, FDA asserts

A controversial GlaxoSmithKline drug for treating Type 2 diabetes no longer will be available through retail pharmacies as of Nov. 18, the Food and Drug Administration announced Wednesday.

May 16, 2011
Amylin accuses Lilly of anticompetitive activity in diabetes drug development, commercialization

Amylin Pharmaceuticals filed suit against Eli Lilly in federal court Monday concerning an agreement between the latter and German drug maker Boehringer Ingelheim to develop drugs for diabetes.

© 2013 Drug Store News. All Rights Reserved.